Loss of TSC1/TSC2 Sensitizes Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

Researchers found that TSC1/TSC2 loss defined a distinct subtype of NSCLC characterized as inflamed tumor microenvironment and superior sensitivity to immune checkpoint blockade.